An In Vitro Microneutralization Assay for SARS-CoV-2 Serology and Drug Screening.
Curr Protoc Microbiol
; 58(1): e108, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-614201
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the city of Wuhan, Hubei Province, China, in late 2019. Since then, the virus has spread globally and caused a pandemic. Assays that can measure the antiviral activity of antibodies or antiviral compounds are needed for SARS-CoV-2 vaccine and drug development. Here, we describe in detail a microneutralization assay, which can be used to assess in a quantitative manner if antibodies or drugs can block entry and/or replication of SARS-CoV-2 in vitro. © 2020 Wiley Periodicals LLC. Basic Protocol 1 Microneutralization assay to test inhibition of virus by antibodies (purified antibodies or serum/plasma) Basic Protocol 2 Screening of anti-SARS-CoV-2 compounds in vitro Support Protocol SARS-CoV-2 propagation.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Neutralization Tests
/
Drug Evaluation, Preclinical
/
Betacoronavirus
/
Antibodies, Viral
Type of study:
Prognostic study
Topics:
Traditional medicine
/
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Curr Protoc Microbiol
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS